Table 2.
Relationship between c-MYC expression and clinicopathological characteristics of colorectal patients treated with 5-FU-based adjuvant chemotherapy after curative surgery
| c-MYC expression | Low | High | |
|---|---|---|---|
| No. of patients | 11 | 9 | P |
| Gender | |||
| Male | 7 (63.6%) | 3 (33.3%) | N.S. |
| Female | 4 (36.4%) | 6 (66.7%) | |
| Age | 70.8 ± 8.7 | 74.3 ± 3.7 | N.S. |
| Location | |||
| Right | 6 (54.5%) | 3 (33.3%) | N.S. |
| Left | 1 (9.1%) | 3 (33.3%) | |
| Rectum | 4 (36.4%) | 3 (33.3%) | |
| Histological grade | |||
| Well | 1 (9.1%) | 1 (11.1%) | N.S. |
| Moderate | 10 (90.9%) | 7 (77.8%) | |
| Poor | 0 (0%) | 1 (11.1%) | |
| Invasion depth | |||
| T2 | 0 (0%) | 1 (11.1%) | N.S. |
| T3 | 11 (100%) | 7 (77.8%) | |
| T4 | 0 (0%) | 1 (11.1%) | |
| Lymphatic metastasis | |||
| Positive | 6 (54.5%) | 6 (66.7%) | N.S. |
| Negative | 5 (45.5%) | 3 (33.3%) | |
| Lymphatic invasion | |||
| Positive | 11 (100%) | 7 (77.8%) | N.S. |
| Negative | 0 (0%) | 2 (22.2%) | |
| Venous invasion | |||
| Positive | 7 (63.6%) | 4 (44.4%) | N.S. |
| Negative | 4 (36.4%) | 5 (55.6%) | |
| Stage (UICC, 2009) | |||
| IIA | 2 (18.2%) | 1 (11.1%) | N.S. |
| IIB | 3 (27.3%) | 2 (22.2%) | |
| IIIA | 1 (9.1%) | 0 (0%) | |
| IIIB | 2 (18.2%) | 3 (33.3%) | |
| IIIC | 3 (27.3%) | 3 (33.3%) | |
| Chemotherapy regimen | |||
| UFT | 4 (36.4%) | 4 (44.4%) | N.S. |
| Xeloda | 2 (18.2%) | 2 (22.2%) | |
| TS-1 | 5 (45.5%) | 3 (33.3%) | |
| Recurrence | |||
| + | 0 (0%) | 7 (77.8%) | 0.0002 |
| − | 11 (100%) | 2 (22.2%) | |